Skip to main content
Premium Trial:

Request an Annual Quote

Biogen Renews, Expands Deal for Lexicon Technology

NEW YORK, Oct. 24-Biogen has renewed and expanded its license for Lexicon Genetics' knockout-based gene targeting technology, Lexicon said today.

 

The agreement expands upon a deal first struck in September 2000, whereby Biogen secured the rights to use Lexicon's "positive negative selection technology," a method to generate knockout mice useful in validating drug targets.

 

This license also gives Biogen non-exclusive rights to Lexicon's isogenic DNA gene targeting technology.

 

Financial details of this agreement were not revealed.

 

For further details, see the press release.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.